Novel Therapies

Novel Therapies groups companies pursuing newer or less established treatment strategies that fall outside traditional small-molecule or standard biologic categories. It is a broad innovation bucket that often overlaps with cell therapy, gene therapy, and next-generation immunotherapy.

Why watch Novel Therapies

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Novel Therapies news

The latest feed items from companies currently grouped under Novel Therapies.

1. 01
   2026-09-11 18:00 EST

   PHARFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

   Source: Pharming Group

2. 02
   2026-09-09 06:00 EST

   PHARPharming Group to participate in September investor conferences

   Source: Pharming Group

3. 03
   2026-08-13 05:00 EST

   PHARPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

   Source: Pharming Group

4. 04
   2026-08-04 06:00 EST

   PHARPharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

   Source: Pharming Group

5. 05
   2026-07-30 05:00 EST

   PHARPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

   Source: Pharming Group

6. 06
   2026-07-16 06:00 EST

   PHARPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

   Source: Pharming Group

7. 07
   2026-06-04 05:00 EST

   PHARPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

   Source: Pharming Group

8. 08
   2026-06-02 06:00 EST

   PHARPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

   Source: Pharming Group

9. 09
   2026-05-28 14:40 EST

   PHARPharming Group announces results of 2026 Annual General Meeting of Shareholders

   Source: Pharming Group

10. 10
    2026-05-22 19:30 EST

    PHAREuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

    Source: Pharming Group

11. 11
    2026-05-07 05:05 EST

    PHARPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

    Source: Pharming Group

12. 12
    2026-05-07 05:00 EST

    PHARPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

    Source: Pharming Group

13. 13
    2026-04-23 06:00 EST

    PHARPharming Group to report first quarter 2026 financial results and provide business update on May 7

    Source: Pharming Group

14. 14
    2026-04-16 06:00 EST

    PHARPharming Group announces the 2026 Annual General Meeting of Shareholders

    Source: Pharming Group

15. 15
    2026-04-07 06:00 EST

    PHARPharming Group to participate in April investor conferences

    Source: Pharming Group

16. 16
    2026-04-02 05:00 EST

    PHARPharming Group announces the filing of its 2025 Annual Report and Form 20-F

    Source: Pharming Group

17. 17
    2026-03-27 06:00 EST

    PHARPharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

    Source: Pharming Group

18. 18
    2026-03-24 06:00 EST

    PHARPharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

    Source: Pharming Group

19. 19
    2026-03-12 06:00 EST

    PHARPharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

    Source: Pharming Group

20. 20
    2026-02-26 07:00 EST

    PHARPharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

    Source: Pharming Group

Companies in Novel Therapies

5 companies tagged with Novel Therapies.

Frequently Asked Questions